VIDEO: CAR T-cell access lags for those with relapsed refractory multiple myeloma
Click Here to Manage Email Alerts
NEW ORLEANS — In this video, Samer Al Hadidi, MD, MS, FACP, discusses an analysis of access to chimeric antigen receptor T-cell therapy presented at the ASH Annual Meeting and Exposition.
"Patients in the real world continue to show responses to this product, but the problem we have in the real world is the availability of those products for patients who need it," Al Hadidi, University of Arkansas for Medical Sciences, said.
In an analysis of clinical outcomes of patients with relapsed refractory multiple myeloma listed to receive CAR-T, Al Hadidi and colleagues found a low cumulative incidence at 12 months of patients in a real-world setting receiving the therapy.
Improved technology to manufacture CAR-T faster is exciting, Al Hadidi said, “Because we may be able to manufacture those products in a quicker way and provide them to patients in a more timely fashion."
Collapse
Al Hadidi, S, et al. Abstract 3588. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Read more about
Click Here to Manage Email Alerts